HC Wainwright Predicts Surrozen FY2024 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Stock analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of Surrozen in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($8.49) for the year. HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. HC Wainwright also issued estimates for Surrozen’s Q4 2024 earnings at ($2.54) EPS, Q1 2025 earnings at ($2.71) EPS, Q2 2025 earnings at ($2.69) EPS, Q3 2025 earnings at ($2.67) EPS, Q4 2025 earnings at ($2.64) EPS, FY2025 earnings at ($10.71) EPS, FY2026 earnings at ($11.68) EPS, FY2027 earnings at ($13.81) EPS, FY2028 earnings at ($15.84) EPS and FY2029 earnings at ($16.24) EPS.

Separately, Guggenheim upgraded Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price target for the company in a report on Friday, January 3rd.

Surrozen Price Performance

NASDAQ:SRZN opened at $11.60 on Monday. Surrozen has a 12 month low of $6.00 and a 12 month high of $18.17. The business’s 50-day moving average is $11.61 and its two-hundred day moving average is $10.15.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.77) by $2.33. The business had revenue of $10.00 million for the quarter.

Institutional Trading of Surrozen

A hedge fund recently raised its stake in Surrozen stock. Stonepine Capital Management LLC boosted its holdings in shares of Surrozen, Inc. (NASDAQ:SRZN) by 66.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 110,000 shares of the company’s stock after purchasing an additional 43,916 shares during the quarter. Surrozen makes up approximately 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 24th largest holding. Stonepine Capital Management LLC owned about 3.43% of Surrozen worth $1,318,000 as of its most recent SEC filing. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.